← All Sponsors
SPONSOR

Oryzon Genomics S.A.

Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
NCT05546580 Phase 1
Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Acute Myeloid Leukemia, in Relapse
United States View Trial →